Loading...
BeiGene, Ltd.
6160.HK•HKSE
HealthcareMedical - Pharmaceuticals
$144.00
$-1.50(-1.03%)
BeiGene, Ltd. (6160.HK) Stock Overview
Explore BeiGene, Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
54.96%
↑ 54.96%
Profit Growth
$-0.28
↑ 26.87%
EPS Growth
$-0.28
↑ 27.69%
Operating Margin
-7.08%
↑ 52.95%
ROE
-11.51%
↑ 26.87%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 6160.HKAnalyst Recommendations details for 6160.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
CEO
Mr. John V. Oyler
Employees
11,000
Headquarters
94 Solaris Avenue, Grand Cayman, MA
Founded
2018